ACTRN12622000680763已完成1 期
To evaluate the safety, tolerability and efficacy in male and female with androgenetic alopecia treated with HMI-115 over a 24-week treatment period
Hope Medicine (Nanjing) Co., Ltd0 个研究点目标入组 16 人开始时间: 2022年5月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
- •2. Male and Female subjects, between 18 and 65 years of , inclusive, at the time of signing informed consent.
- •3. Clinical diagnosis of androgenetic alopecia. Male subjects who meet Norwood-Hamilton scales 3v, 4 and 5. Female subjects who meet Sinclair scales 2-4.
排除标准
- •1. Subject with clinical diagnosis of non-AGA (Androgenetic Alopecia_
- •2. Subject with clinically relevant abnormal skin or scalp findings which could interfere study assessment
- •3. Subject has used therapies associated with hair growth or therapy with confirmed effects on PRL level, within defined time window before screening.
- •4. Subject with history of another pituitary, posterior pituitary, or hyperthyroidism
- •5. Subject has clinically significantly abnormal laboratory tests at Screening
- •6. Known hypersensitivity to any of the IMP (Investigational Medicinal Product) ingredients
- •7. Any other conditions in the investigator's opinion that prevent the subject from participating
研究者
相似试验
已完成
不适用
To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patientsHaemophiliaHaematological DisordersISRCTN02847428Baxter (Italy)11
已完成
3 期
Clinical study on Abhraloha in iron deficiency AnemiaCTRI/2019/01/017303Shree Dhootapapeshwar Limited57
进行中（未招募）
1 期
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12
已完成
1 期
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN)M32.1Systemic lupus erythematosus with organ or system involvementDRKS00004858Charité - Universitätsmedizin Berlin10
进行中（未招募）
1 期
Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19).The study population will consist of adults (18-80 years old) hospitalised for =48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test positive from nasopharyngeal swab. Patients with ARDS or patients requiring mechanical ventilation at screening or randomisation will be excludedMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002295-13-FRAssistance Publique - Hôpitaux Paris100